23-NHL-33-RG (R1979-ONC-2075): A Phase 3, Open-Label, Randomized Study to Compare the Safety and Efficacy of Odronextamab (REGN1979), An Anti-CD20 X Anti-CD3 Bispecific Antibody, Combined with Chemotherapy Versus Rituximab Combined with Chemotherapy In Pr

Detalles del proyecto

EstadoActivo
Fecha de inicio/Fecha fin1/30/24 → 1/30/27

Financiación

  • Regeneron Pharmaceuticals: 67.805,00 US$